



Delcath to Present at Upcoming Investor Conferences

March 2, 2011

NEW YORK, March 2, 2011 /PRNewswire via COMTEX/ --

Delcath Systems, Inc. (Nasdaq: DCTH) announced today that executive management will present an overview of the Company's business strategy and recent corporate developments at the following investor conferences:

- The Cowen and Company Healthcare Conference in Boston. Mr. Eamonn Hobbs, Chief Executive Officer, and Mr. David McDonald, Chief Financial Officer, are scheduled to present an overview of the Company on Tuesday, March 8, 2011 at 10:15 a.m. ET.
- ROTH Capital Annual OC Growth Stock Conference in Laguna Niguel, California. Mr. Hobbs is scheduled to present an overview of the Company on Monday, March 14, 2011 at 1:30 p.m. PT.

Attendance at each of these conferences is by invitation only. Delcath will offer live and audio webcasts of its presentation, which may be accessed on the Investor Relations section of the Company's website at www.delcath.com. An archived replay of the presentations will be available for 90 days, also at www.delcath.com.

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact Information:

Investor Contact:	Media Contact:
Gregory Gin/Doug Sherk	Janine McCargo
EVC Group	EVC Group
646-445-4801/415-896-6818	646-688-0425

SOURCE Delcath Systems, Inc.